RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
Min A, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, Kim HP, Lee KH, Han SW, Oh DY, Kim TY, O'Connor MJ, Kim WH, Bang YJ.
Min A, et al.
Mol Cancer Ther. 2013 Jun;12(6):865-77. doi: 10.1158/1535-7163.MCT-12-0950. Epub 2013 Mar 19.
Mol Cancer Ther. 2013.
PMID: 23512992